Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy-Reference-Cited by-同舟云学术

Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy

Published:2023-02 Issue:2 Volume:33 Page:199-207
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Moore Ursula,Fernández-Simón Esther,Schiava Marianela,Cox Dan,Gordish-Dressman Heather,James Meredith K.,Mayhew Anna,Wilson Ian,Guglieri Michela,Rufibach Laura,Blamire Andrew,Carlier Pierre G.,Mori-Yoshimura Madoka,Day John W.,Jones Kristi J.,Bharucha-Goebel Diana X.,Salort-Campana Emmanuelle,Pestronk Alan,Walter Maggie C.,Paradas Carmen,Stojkovic Tanya,Bravver Elena,Pegoraro Elena,Mendell Jerry R.,Bushby Kate,Diaz-Manera Jordi,Straub Volker^ORCID

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference41 articles.

1. A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p;Bashir;Hum Mol Genet,1994

2. Linkage of Miyoshi myopathy (distal autosomal recessive muscular dystrophy) locus to chromosome 2p12-14;Bejaoui;Neurology,1995

3. Miyoshi Myopathy and Limb Girdle Muscular Dystrophy R2 are the same disease;Moore;Neuromuscul Disord,2021

4. Late onset in dysferlinopathy widens the clinical spectrum;Klinge;Neuromuscul Disord,2008

5. The Clinical Outcome Study for dysferlinopathy: an international multicenter study;Harris;Neurol Genet,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients;International Journal of Molecular Sciences;2024-08-12

2. ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome;JCI Insight;2024-03-05

3. Serum myostatin as a candidate disease severity and progression biomarker of spinal muscular atrophy;Brain Communications;2024